Trial · NCT06469645
The Role of SGLT2i in Management of Moderate AS
NCT06469645, Phase 2, Phase 3, Completed, University of East Anglia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of SGLT2i in Management of Moderate AS. Trials, record NCT06469645. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06469645
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of SGLT2i in Management of Moderate AS
- NCT number
- NCT06469645
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 104 participants, actual
- Lead sponsor
- University of East Anglia
- Conditions
- Moderate Aortic Valve Stenosis
- Interventions
- Empagliflozin 10 MG
- First posted
- 2024-06-21
- Last updated
- 2026-07-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in indexed extracellular volume (iECV) | 6 months | The indexed extracellular volume (iECV) (expressed in ml/m2) will be assessed from the Cardiac Magnetic Resonance Scan at baseline and at 6 months follow-up |
| Secondary | Change in left ventricular ejection fraction | 6 months | Left ventricular ejection fraction (expressed in percentage, %) will be assessed from the Cardiac Magnetic Resonance Scan at baseline and at 6 months follow-up |
| Secondary | Change in left ventricular diastolic function as assessed by the E/A ratio | 6 months | Diastolic function will be assessed from the echocardiographic assessment at baseline and at 6 months follow-up |
| Secondary | Change in indexed left ventricular mass | 6 months | Change in indexed left ventricular mass (expressed in g/m2) will be assessed from the Cardiac Magnetic Resonance Scan at baseline and at 6 months follow-up |
| Secondary | Change in percentage of myocardial uptake of late gadolinium enahncement (LGE) | 6 months | The late gadolinium enhancement will be assessed visually and quantitatively (% of left ventricular mass) from the Cardiac Magnetic Resonance Scan at baseline and at 6 months follow-up |
| Secondary | Change in cardiac markers (N-terminal pro b-type natriuretic peptide and high sensitivity troponin) | 6 months | Participants will have their cardiac markers (N-terminal pro b-type natriuretic peptide and high sensitivity troponin) tested at baseline and at the 6-month follow-up visit. |
| Secondary | Change in peak oxygen consumption (VO2) as assessed by Cardio-Pulmonary Exercise Test | 6 months | Participants will undergo a Cardio-pulmonary Exercise Test at baseline and at 6-months follow-up. The peak oxygen consumption will be assessed and changes will be recorded. |
| Secondary | Change in Quality of Life (QoL) as assessed with the Kansas City Cardiomyopathy Questionnaire | 6 months | Participants will complete the Kansas City Cardiomyopathy Questionnaire at the baseline visit and at the 6-month follow up visit. The score of the Questionnaire scales from 0 to 100, with 0 denoting the worst and 100 the best possible status. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06469645
GET https://conductscience.org/api/trials/v1/NCT06469645/registered